Today: 30 April 2026
Browse Category

NASDAQ:GH 30 October 2025 - 21 January 2026

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
21 January 2026
·····
Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next

Guardant Health shares jumped 7.2% to $109.24 Tuesday, nearing their 52-week high, despite Evercore ISI downgrading the stock while raising its price target to $105. A Form 4 filing showed Chief People Officer Terilyn J. Monroe received 17,555 shares through vested stock units. Shares have climbed about 200% in the past year. Investors are watching Medicare reimbursement rates for Guardant’s Shield blood test.
6 January 2026
·
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health shares soared nearly 30% to around $94 on Oct. 30, 2025, after Q3 revenue jumped 39% to $265.2 million, beating estimates. The company raised its 2025 revenue outlook to $965–970 million. New partnerships are expanding access to its Shield colorectal cancer test nationwide. Guardant360 received additional FDA approvals and a formal review submission.
30 October 2025
··

Stock Market Today

  • Why Investors Are Focused on Vaidya Sane Ayurved Laboratories (NSE:MADHAVBAUG) Amid Growth and High Insider Ownership
    April 29, 2026, 10:29 PM EDT. Vaidya Sane Ayurved Laboratories (NSE:MADHAVBAUG) has attracted investor attention due to its strong financial performance and insider alignment. The company has delivered a compound annual EPS growth of 19% over the past three years, signaling sustained earnings momentum. Revenue growth and an improved EBIT margin, up by 6.6 percentage points to 11%, underscore operational strength. With insiders owning 78% of the firm, alignment between management and shareholders is notably high, reducing agency risk. Valued at ₹2.5 billion, the company appeals to investors favoring profitable, growing firms over speculative ventures without revenue or profit history. This combination of growth, profitability, and insider confidence makes Vaidya Sane a compelling pick in the Ayurvedic healthcare sector.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Go toTop